|Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE …|
LQM Chow, R Haddad, S Gupta, A Mahipal, R Mehra, M Tahara, R Berger, ...
Journal of Clinical Oncology 34 (32), 3838, 2016
|Evolution of neoantigen landscape during immune checkpoint blockade in non–small cell lung cancer|
V Anagnostou, KN Smith, PM Forde, N Niknafs, R Bhattacharya, J White, ...
Cancer discovery 7 (3), 264-276, 2017
|Pembrolizumab for platinum-and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study|
J Bauml, TY Seiwert, DG Pfister, F Worden, SV Liu, J Gilbert, NF Saba, ...
Journal of Clinical Oncology 35 (14), 1542, 2017
|Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas|
Y Wang, S Springer, CL Mulvey, N Silliman, J Schaefer, M Sausen, ...
Science translational medicine 7 (293), 293ra104-293ra104, 2015
|Emerging biomarkers in head and neck cancer in the era of genomics|
H Kang, A Kiess, C Chung
Nature Reviews Clinical Oncology, 2014
|Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012|
R Mehra, TY Seiwert, S Gupta, J Weiss, I Gluck, JP Eder, B Burtness, ...
British journal of cancer 119 (2), 153-159, 2018
|Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing|
CH Chung, VB Guthrie, DL Masica, C Tokheim, H Kang, J Richmon, ...
Annals of oncology 26 (6), 1216-1223, 2015
|Head and neck PET/CT: therapy response interpretation criteria (Hopkins criteria)—interreader reliability, accuracy, and survival outcomes|
C Marcus, A Ciarallo, AK Tahari, E Mena, W Koch, RL Wahl, AP Kiess, ...
Journal of Nuclear Medicine 55 (9), 1411-1416, 2014
|Differences in the prevalence of human papillomavirus (HPV) in head and neck squamous cell cancers by sex, race, anatomic tumor site, and HPV detection method|
G D’Souza, WH Westra, SJ Wang, A Van Zante, A Wentz, N Kluz, E Rettig, ...
JAMA oncology 3 (2), 169-177, 2017
|Efficacy of Selpercatinib in RET-Altered Thyroid Cancers|
LJ Wirth, E Sherman, B Robinson, B Solomon, H Kang, J Lorch, F Worden, ...
New England Journal of Medicine 383 (9), 825-835, 2020
|Whole-exome sequencing of salivary gland mucoepidermoid carcinoma|
H Kang, M Tan, JA Bishop, S Jones, M Sausen, PK Ha, N Agrawal
Clinical Cancer Research 23 (1), 283-288, 2017
|Salivary Secretory Carcinoma With a Novel ETV6-MET Fusion: Expanding the Molecular Spectrum of a Recently Described Entity|
L Rooper, K Theodoros, Y Ning, J Bishop, S Gordon, H Kang
American Journal of Surgical Pathology, 2018
|Evaluation of proposed staging systems for human papillomavirus‐related oropharyngeal squamous cell carcinoma|
IJ Malm, CJ Fan, LX Yin, DX Li, WM Koch, CG Gourin, KT Pitman, ...
Cancer 123 (10), 1768-1777, 2017
|High-resolution microbiome profiling uncovers Fusobacterium nucleatum, Lactobacillus gasseri/johnsonii, and Lactobacillus vaginalis associated to oral and oropharyngeal cancer …|
R Guerrero-Preston, JR White, F Godoy-Vitorino, A Rodríguez-Hilario, ...
Oncotarget 8 (67), 110931, 2017
|Salivary duct carcinoma: an aggressive salivary gland malignancy with opportunities for targeted therapy|
NC Schmitt, H Kang, A Sharma
Oral oncology 74, 40-48, 2017
|Genomic determinants of response to pembrolizumab in head and neck squamous cell carcinoma (HNSCC).|
RI Haddad, TY Seiwert, LQM Chow, S Gupta, J Weiss, I Gluck, JP Eder, ...
Journal of Clinical Oncology 35 (15_suppl), 6009-6009, 2017
|FDG PET/CT in the management of nasopharyngeal carcinoma|
A Mohandas, C Marcus, H Kang, MT Truong, RM Subramaniam
American Journal of Roentgenology 203 (2), W146-W157, 2014
|SMAD4 loss is associated with cetuximab resistance and induction of MAPK/JNK activation in head and neck cancer cells|
H Ozawa, RS Ranaweera, E Izumchenko, E Makarev, A Zhavoronkov, ...
Clinical Cancer Research 23 (17), 5162-5175, 2017
|Personalized medicine in the oncology clinic: implementation and outcomes of the Johns Hopkins molecular tumor board|
WB Dalton, PM Forde, H Kang, RM Connolly, V Stearns, CD Gocke, ...
JCO precision oncology 1, 1-19, 2017
|Class I HDACs Are Mediators of Smoke Carcinogen–Induced Stabilization of DNMT1 and Serve as Promising Targets for Chemoprevention of Lung Cancer|
SA Brodie, G Li, A El-Kommos, H Kang, SS Ramalingam, M Behera, ...
Cancer prevention research 7 (3), 351-361, 2014